- Conditions
- Synovial Sarcoma, Myxoid Liposarcoma
- Interventions
- afamitresgene autoleucel (previously ADP-A2M4)
- Genetic
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 10 Years to 75 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2038
- U.S. locations
- 17
- States / cities
- Duarte, California • Palo Alto, California • Aurora, Colorado + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 841–864
of 18,611
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HCV Infection
- Interventions
- GS-5885, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 13
- States / cities
- Anaheim, California • Cypress, California • National City, California + 10 more
- Conditions
- Advanced Solid Tumors
- Interventions
- REGN7075, Cemiplimab, Platinum-based doublet chemotherapy, Bevacizumab, Trifluridine-tipiracil
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 548 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 20
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 15 more
- Conditions
- Renal Impairment
- Interventions
- Mezigdomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 82 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Miami Lakes, Florida • Orlando, Florida
- Conditions
- Leukemia, Acute Myeloid Leukemia
- Interventions
- Selinexor, Sorafenib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy, Asthma
- Interventions
- JNJ-43260295, Placebo, Nasal Allergen Challenge
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor, Solid Tumor, Metastatic Solid Tumor, Metastasis to Soft Tissue, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma
- Interventions
- tolododekin alfa, Cemiplimab
- Drug
- Lead sponsor
- Ankyra Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 4
- States / cities
- Bethesda, Maryland • Boston, Massachusetts • Portland, Oregon + 1 more
- Conditions
- Healthy Volunteers
- Interventions
- Zasocitinib, COC, Metformin, Digoxin, Esomeprazole
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Systemic Sclerosis, Scleroderma
- Interventions
- Tofacitinib, Placebo Oral Tablet
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Pittsburgh, Pennsylvania
- Conditions
- Healthy
- Interventions
- Pioglitazone, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 55 Years to 83 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Healthy Subjects
- Interventions
- Ziresovir, Placebo
- Drug · Other
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey
- Conditions
- Lung Cancer
- Interventions
- autologous tumor cell vaccine, therapeutic autologous dendritic cells, adjuvant therapy, biological therapy, conventional surgery, surgery, tumor cell derivative vaccine, vaccine therapy
- Drug · Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Healthy Volunteers
- Interventions
- TEV-56286, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Miramar, Florida
- Conditions
- Hepatic Impairment
- Interventions
- ABL001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
- Conditions
- Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Childhood Angiosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Mesenchymoma, Childhood Malignant Peripheral Nerve Sheath Tumor, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Childhood Synovial Sarcoma, Dermatofibrosarcoma Protuberans, Malignant Adult Hemangiopericytoma, Malignant Childhood Hemangiopericytoma, Metastatic Childhood Soft Tissue Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
- Interventions
- Cixutumumab, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 13
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 10 more
- Conditions
- Covid19
- Interventions
- Famotidine, N-Acetyl cysteine
- Drug
- Lead sponsor
- Prisma Health-Upstate
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Easley, South Carolina • Greenville, South Carolina • Greer, South Carolina
- Conditions
- Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain, Glioma of Brainstem, Anaplastic Astrocytoma, Pilomyxoid Astrocytoma, Mixed Oligodendroglioma-Astrocytoma, Brain Stem Glioma, Diffuse Intrinsic Pontine Glioma
- Interventions
- SIACI of Erbitux and Bevacizumab
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Oral Cavity Squamous Cell Carcinoma
- Interventions
- NisinZ® P, Surgery (non-interventional, standard of care)
- Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Ischemic Heart Disease
- Interventions
- GS-6615, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Wounds and Injuries
- Interventions
- Processed Amniotic Fluid, Standard of Care Wound Treatment Regimen
- Drug · Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- NSCLC, Melanoma
- Interventions
- BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta)
- Biological · Drug
- Lead sponsor
- BioAtla, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Atlanta, Georgia • Dyer, Indiana + 5 more
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Elastography, Multigated Acquisition Scan, Necitumumab, Osimertinib
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 15
- States / cities
- Duarte, California • Palo Alto, California • Sacramento, California + 7 more
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Interventions
- NBF-006
- Drug
- Lead sponsor
- Nitto BioPharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 9
- States / cities
- Beverly Hills, California • La Jolla, California • Tampa, Florida + 6 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- AMG 127, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Lake Forest, California • Aventura, Florida